Compare AbCellera Biologics Inc (ABCL) vs Avantis US Small Cap Value ETF (AVUV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Avantis US Small Cap Value ETF — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while Avantis US Small Cap Value ETF trades at $122.18. The key difference: Avantis US Small Cap Value ETF is trading nearer its 52-week high, AbCellera Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | AVUV | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | Sector/Thematic |
52-Week High | $8.12 | $124.94 |
52-Week Low | $2.78 | $90.37 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
AVUV trades at $123.82, up 0.25% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF's small-cap value focus has gained attention amid a market rotation, with recent news highlighting its outperformance versus growth peers and potential benefits from shifting rate expectations. Support and resistance levels are closely watched near current prices.
The outlook for AVUV hinges on continued small-cap value strength, though exposure to regional banks and sensitivity to interest rates pose risks. Its active management approach aims to capture the value premium, but elevated volatility relative to large-caps remains a consideration for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Avantis US Small Cap Value ETF
AVUV is an actively managed ETF that targets small-cap value companies in the United States. It uses a systematic, rules-based process to identify firms with low valuations and high profitability, aiming to capture the historical premiums of 'size' and 'value' while filtering for financial quality.
Read more on AVUV →
